Gewinn- und Verlustrechnung von APA Corporation

U.S. Patent 12,679,817, covering novel processes for preparing the (R)- and (S)-enantiomers of MDMA and MBDB, granted to PharmAla by the US Patent and Trademark Office (USPTO) PharmAla has exercised its option to cancel the proposed licensing of APA-01 to Restora Neurosciences, and will evaluate in-house and co-development pathways Canaccord Genuity LLC has been engaged as exclusive financial advisor and placement agent TORONTO, Aug. 21, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), today announced three corporate updates. 1.  U.S. Patent Granted for Novel Enantioselective Manufacturing Processes PharmAla has been granted United States Patent No.

Four grants generate $2.6 million in conservation impact to enhance grassland habitat, restore aquatic habitats and conserve desert fish species found nowhere else in the world Four grants generate $2.6 million in conservation impact to enhance grassland habitat, restore aquatic habitats and conserve desert fish species found nowhere else in the world

ALBUQUERQUE, N.M., Aug. 20, 2026 (GLOBE NEWSWIRE) -- ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology and fixed-tilt products, foundation solutions, software systems and services, will host its previously announced APA Investor Technology Showcase today, Thursday, August 20, 2026, beginning at 9:00 a.m.

APA Group Stapled Securities (APAJF) Q4 2026 Earnings Call Transcript

On June 30, 2026, Hotchkis and Wiley filed a 13DG report with the Securities and Exchange Commission, disclosing a reduction of 319,811 shares in APA Corp (NASDAQ

APA NASDAQ: APA outlined a strategy centered on cash-generating operations in the Permian Basin and Egypt, cost reductions and a global exploration portfolio that management believes can support future production growth.

APA Corporation remains a Strong Buy, driven by robust free cash flow, upsized cost savings, and upside from the Suriname project. APA beat top- and bottom-line estimates again, raised 2026 Permian oil guidance, and maintained capital discipline, with net leverage at a solid ~0.6x. Debt reduction and cost savings are on track, with $752 million in bond repayments in H1 2026 and $675 million in annualized cost/interest benefits.

APA has jumped nearly 100% over the last year, while Woodside Energy Group ADR is up by 32% year to date.

APA's lower costs, stronger Permian efficiency and discounted valuation support the case, but commodity sensitivity and long project timelines temper upside.

APA Corporation has prioritized strict deleveraging, portfolio consolidation, and disciplined capital returns over unbridled production growth since its 2021 reorganization. Recent milestones include the $4.5B Callon Petroleum acquisition, a structural cost-reduction target raised to $500M, and $230M worth of GranMorgu offshore development funding. Technical analysis reveals a confluence of nominal and commodity-ratio targets pointing to a near-term price level of ~$51.95 (an implied ~30% upside), with macro-fractal extensions reaching significantly higher.